Filing Date Form TypeDescription   
   
Data pager
 Page 1 of 14, items 1 to 13 of 182.
2020-08-078-KCurrent report, items 8.01 and 9.01 Acc-no: 0001213900-20-020897 (34 Act)  Size: 147 KB
2020-08-068-KCurrent report, items 2.02 and 9.01 Acc-no: 0001213900-20-020662 (34 Act)  Size: 112 KB
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001213900-20-020373 (34 Act)  Size: 2 MB
2020-08-038-KCurrent report, items 8.01 and 9.01 Acc-no: 0001213900-20-019888 (34 Act)  Size: 32 KB
2020-07-308-KCurrent report, items 8.01 and 9.01 Acc-no: 0001213900-20-019177 (34 Act)  Size: 14 MB
2020-07-288-KCurrent report, items 8.01 and 9.01 Acc-no: 0001213900-20-018871 (34 Act)  Size: 23 KB
2020-07-218-K/A[Amend] Current report, items 8.01 and 9.01 Acc-no: 0001213900-20-018013 (34 Act)  Size: 36 KB
2020-07-208-KCurrent report, items 8.01 and 9.01 Acc-no: 0001213900-20-017924 (34 Act)  Size: 34 KB
2020-07-16424B5Prospectus [Rule 424(b)(5)]Acc-no: 0001213900-20-017634 (33 Act)  Size: 298 KB
2020-07-168-KCurrent report, items 1.01, 8.01, and 9.01 Acc-no: 0001213900-20-017615 (34 Act)  Size: 329 KB
2020-07-15424B5Prospectus [Rule 424(b)(5)]Acc-no: 0001213900-20-017565 (33 Act)  Size: 296 KB
2020-07-138-KCurrent report, items 8.01 and 9.01 Acc-no: 0001213900-20-017343 (34 Act)  Size: 7 MB
2020-07-108-KCurrent report, items 8.01 and 9.01 Acc-no: 0001213900-20-017207 (34 Act)  Size: 48 KB


INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business Update
8/5/2020 8:01:00 PM

The company will host an earnings call: Today, August 5 at 4:30 PM ETLA JOLLA, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease today reported its financial results for the second quarter ended June 30, 2020 and is providing a business update. INmune Bio will hold a conference call today at 4:30 PM Eastern Time. To participate in the call, please dial 415-226-5355 five minutes before the scheduled time. “In the second quarter, and year to date, INmune Bio continued to progress forward with both of our clinical platforms,” stated RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “We announced interim Phase Ib data demonstrating that our Alzheimer’s Disease candidate, XPro1595, can reduce neuroinflammation. Our progress with XPro1595 supports our overall strategy to create platforms of therapeutics, based on reducing inflammation by targeting the innate immune system to fight disease.  We are planning a number of programs employing this approach in NASH, MUC4 expressing HER2+ cancer, ALS and complications of cytokine storm caused by COVID-19.  With the Natural Killer Priming platform, we anticipate INKmune™ Phase I in high-risk MDS to start the second half of this year.”Q2 2020 and Recent Corporate Highlights DN-TNF Platform Highlights: * Announced interim Phase Ib data demonstrating that XPro1595 decreases neuroinflammation in patients with Alzheimer's Disease - XPro1595 reduced neuroinflammation by 40.6% in a white matter tract important for learning and memory. * Announced combination therapy of Lapatinib with INB03 may be used to overcome resistance to trastuzumab in women with MUC4+/HER2+ breast cancer.  This work was presented at the AACR 2020 by Dr. Roxana Schillaci and may form the basis for a Phase II program in patients with MUC4 expressing HER2+ cancer. * Initiated a clinical program to test targeting soluble TNF (Quellor™), one of the key components of the cytokine storm, using our TNF Inhibitor (DN-TNF) Platform to prevent complications of COVID-19 infection.  * Frontiers in Oncology published an invited entitled Tumor Necrosis Factor α Blockade: an Opportunity to Tackle Breast Cancer by Prof. Roxana Schillaci, a leader in the field of TNF in cancer.NK Priming Platform Highlights: * Received regulatory clearance from UK MHRA to initiate a Phase I Trial of INKmune in patients with high-risk MDS - study will be the first-in man trial for INKmune – a novel therapy to prime the patient’s own NK cells to attack their cancer. * Announced allowance of U.S. Patent covering method for treating cancer by in-vivo priming of natural killer cells. * Received notice of allowance in counterpart patent in Australia covering method for treating cancer by in-vivo priming of natural killer cells. * Announced publication of a review article: Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer in the journal Stem Cells Translational Medicine by Prof. Mark Lowdell, Co-Founder and CSO of INmune Bio, Inc.  The article reviews the potential of harnessing cells of the innate immune system to treat cancer.Financial Highlights: * Closed a $25 million gross proceeds public offering of common stock, including full exercise of Underwriters’ Over-Allotment Option resulting in net proceeds of approximately $23.1 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.Upcoming Milestones: * Report additional data on Phase 1b XPro1595 in Alzheimer’s Disease in 2H 2020. * Enroll first patient in Phase II Quellor™ program, targeting COVID-19 patients with immune mediated complications from COVID-19. * Enroll first patient in Phase I INKmune™ in High Risk MDS cancer, expected 2H20. * Enroll first patient in Phase I INKmune™ in Ovarian cancer, expected mid-2021.Financial Results for the Second Quarter Ended June 30, 2020:Net loss attributable to common stockholders for the second quarter ended June 30, 2020 was $2.1 million, compared to $0.4 million for the quarter ended June 30, 2019.Research and development expense totaled approximately $0.9 million for the second quarter ended June 30, 2020, compared to approximately $0.6 million during the second quarter ended June 30, 2019.General and administrative expense was approximately $1.2 million for the quarter ended June 30, 2020, compared to approximately $1.3 million during the second quarter ended June 30, 2019.As of June 30, 2020, the Company had cash and cash equivalents of approximately $4.8 million with no debt. Subsequent to the quarter end, INmune Bio closed a $25 million gross proceeds public offering of common stock resulting in net proceeds of approximately $23.1 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.As of August 5, 2020, the Company had approximately 13.4 million common shares outstanding.Earnings Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.Date: August 5, 2020 Time: 4:30 PM Eastern Time Participant Dial-in: 1-415-226-5355About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.  The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer.  INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.Information about Forward-Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, Quellor™, XPro1595, LIVNate™, and INKmune™ are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.INmune Bio Contact:  David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact:  James Carbonara (646) 755-7412 James@haydenir.comThe following table summarizes our results of operations for the periods indicated:INMUNE BIO, INC. CONSOLIDATED BALANCE SHEETS (Unaudited) June 30, 2020  December 31, 2019         ASSETS        CURRENT ASSETS        Cash and cash equivalents$4,816,561  $6,995,525  Research and development tax credit receivable 1,044,843   568,139  Other tax receivable 155,000   77,225  Prepaid expenses 342,492   97,623  Prepaid expenses – related party -   26,266           TOTAL CURRENT ASSETS 6,358,896   7,764,778           Operating lease – right of use asset – related party 174,649   191,543  Acquired in-process research and development intangible assets 16,514,000   16,514,000           TOTAL ASSETS$23,047,545  $24,470,321           LIABILITIES AND STOCKHOLDERS’ EQUITY                 CURRENT LIABILITIES        Accounts payable and accrued liabilities$624,893  $401,989  Accounts payable and accrued liabilities – related parties 223,562   290,102  Deferred liabilities 361,842   -  Operating lease, current liability – related party 6,950   8,288  TOTAL CURRENT LIABILITIES 1,217,247   700,379           Long-term operating lease liability – related party 145,430   160,164  TOTAL LIABILITIES 1,362,677   860,543           COMMITMENTS AND CONTINGENCIES                 STOCKHOLDERS’ EQUITY        Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding -   -  Common stock, $0.001 par value, 200,000,000 shares authorized, 10,897,630 and 10,770,948 shares issued and outstanding, respectively 10,898   10,771  Additional paid-in capital 47,068,236   44,833,703  Common stock issuable 50,000   50,000  Accumulated other comprehensive loss 10,126   (8,515) Accumulated deficit (25,454,392)  (21,276,181) TOTAL STOCKHOLDERS' EQUITY 21,684,868   23,609,778           TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$23,047,545  $24,470,321            INMUNE BIO, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) For the Three Months Ended June 30,  For the Six Months Ended June 30,   2020  2019  2020  2019  REVENUE$-  $-  $-  $-                   OPERATING EXPENSES                General and administrative 1,204,366   1,335,727   2,503,840   2,634,106  Research and development 903,043   634,696   1,695,830   1,247,404  Waiver of common stock issuable -   (1,542,000)  -   (1,542,000) Total operating expenses 2,107,409   428,423   4,199,670   2,339,510                   LOSS FROM OPERATIONS (2,107,409)  (428,423)  (4,199,670)  (2,339.510)                  OTHER (EXPENSE) INCOME (395)  36,340   21,459   46,382                   NET LOSS$(2,107,804) $(392,083) $(4,178,211) $(2,293,128)                  Net loss per common share – basic and diluted$(0.20) $(0.04) $(0.39) $(0.23)                  Weighted average common shares outstanding - basic and diluted 10,800,708   10,150,810   10,774,004   9,771,833                   COMPREHENSIVE LOSS                Net loss$(2,107,804) $(392,083) $(4,178,211) $(2,293,128) Other comprehensive gain (loss) – gain (loss) on foreign currency translation 39,378   (25,014)  18,641   (25,736)                  Total comprehensive loss$(2,068,426) $(417,097) $(4,159,570) $(2,318,864)                  INMUNE BIO, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) For the Six Months Ended June 30,   2020  2019  CASH FLOWS FROM OPERATING ACTIVITIES:        Net loss$(4,178,211) $(2,293,128) Adjustments to reconcile net loss to net cash used in operating activities:        Stock-based compensation 1,363,410   1,949,395  Waiver of common stock issuable -   (1,542,000) Changes in operating assets and liabilities:        Research and development tax credit receivable (476,704)  (251,472) Other tax receivable (77,775)  (67,315) Joint development cost receivable -   (31,340) Prepaid expenses (244,869)  (184,472) Prepaid expenses – related party 26,266   (244,882) Accounts payable and accrued liabilities 222,904   (115,004) Accounts payable and accrued liabilities – related parties 149,221   (200,654) Deferred liabilities 361,842   -  Operating lease liability – related party 822   (24,653) Net cash used in operating activities (2,853,094)  (3,005,525)          CASH FLOWS FROM FINANCING ACTIVITIES:        Net proceeds from sale of common stock 1,667,489   12,209,021  Purchase of common stock (1,012,000)  -  Net cash provided by financing activities 655,489   12,209,021           Impact on cash from foreign currency translation 18,641   (25,736)          NET (DECREASE) INCREASE IN CASH (2,178,964)  9,177,760           CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 6,995,525   186,204           CASH AND CASH EQUIVALENTS AT END OF PERIOD$4,816,561  $9,363,964           SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:        Cash paid for income taxes$-  $-  Cash paid for interest expense$-  $-           NONCASH INVESTING AND FINANCING ACTIVITIES:        Capital contribution$215,761  $-  Issuance of warrants to placement agents$-  $247,452  Issuance of common stock issuable$-  $3,084,000

INmune Bio, Inc to Present at the BTIG Virtual Biotechnology Conference 2020
8/3/2020 11:00:00 AM

LA JOLLA, Calif, Aug. 03, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that management will be presenting a corporate overview at the BTIG Virtual Biotechnology Conference being held August 10-11, 2020 and will also be available for 1x1 meetings. To schedule a meeting, please contact your BTIG representative or email James@HaydenIR.com.       INmune Bio Fireside Chat Details:BTIG Virtual Biotechnology Conference 2020 Date:  Monday, August 10, 2020 Presentation Time:  1:00 - 1:25 PM ETAbout INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.  The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer.  INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Forward-Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, including without limitation statements regarding the completion and timing of the offering and the amount and use of proceeds therefrom, are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate, Quellor™ and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.      INmune Bio Contact: David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact: James Carbonara, Hayden IR (646) 755-7412 james@haydenir.com

INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results
7/31/2020 11:00:00 AM

LA JOLLA, Calif, July 31, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on August 5, 2020 at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2020. Conference Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Second Quarter Conference Call when reaching an operator.Date: August 5, 2020 Time: 4:30 PM Eastern Time Participant Dial-in: 212-231-2931A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available for approximately one week by calling 412-317-6671 and entering PIN no. 21967252.About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.Forward-Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, including without limitation statements regarding the completion and timing of the offering and the amount and use of proceeds therefrom, are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate™, Quellor™ and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.INmune Bio Contact:  David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact: James Carbonara, Hayden IR (646) 755-7412 james@haydenir.com

INmune Bio, Inc. Featured on Fox News (VIDEO): STNF and Cytokine Storm
7/27/2020 11:00:00 AM

LA JOLLA, Calif, July 27, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease was featured on a Fox Business News segment. Fox Business News reports: “INmune Bio CEO, President and acting CMO Dr. Raymond Tesi, M.D. talks about INmune Bio's proposed phase two human trials of possible treatment of coronavirus patients using an anti-inflammatory drug and addresses the effort for lower drug costs.” To watch the full interview, please visit the link below: https://video.foxbusiness.com/v/6174850319001/?playlist_id=937116503001sp=show-clipsAbout INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.  The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer.  INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Forward Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate™, Quellor™ and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.    INmune Bio Contact: David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact: James Carbonara (646) 755-7412 James@haydenir.com

Correction: INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option
7/20/2020 8:57:53 PM

LA JOLLA, Calif., July 20, 2020 -- In a release issued under the same headline on Monday, July 20th by INmune Bio, Inc. (NASDAQ: INMB) was incorrectly reported with below.

INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option
7/20/2020 5:07:10 PM

LA JOLLA, Calif., July 20, 2020 -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that.

INmune Bio, Inc. Prices Public Offering of Common Stock
7/16/2020 1:15:10 PM

LA JOLLA, Calif, July 16, 2020 --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that.

INmune Bio, Inc. Announces Proposed Public Offering of Common Stock
7/15/2020 8:10:47 PM

LA JOLLA, Calif., July 15, 2020 -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments that.

Tiny Biotech Skyrockets To A Record High On Promising Alzheimer's News
7/14/2020 8:16:16 PM

Inmune Bio stock skyrocketed to a record high Tuesday after the biotech company unveiled promising results for its Alzheimer's treatment. The drug targets inflammation in the brain.

The Daily Biotech Pulse: Blueprint, Roche Ink $1.7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits
7/14/2020 12:04:55 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) * Altimmune Inc (NASDAQ: ALT) (announced positive preclinical data for its intranasal vaccine candidate AdCOVID) * argenx SE - ADR (NASDAQ: ARGX) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) (reacted to preliminary second-quarter results) * Beigene Ltd (NASDAQ: BGNE) - announced $421 million in additional investment by Amgen, Inc. (NASDAQ: AMGN) in a $2.1-billion direct offering by the Chinese biotech * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) * Catalent Inc (NYSE: CTLT) * DexCom, Inc. (NASDAQ: DXCM) * Equillium Inc (NASDAQ: EQ (announced positive results for COVID-19 study of the drug it is co-developing with India's Biocon) * Fulgent Genetics Inc (NASDAQ: FLGT) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Heat Biologics Inc (NASDAQ: HTBX) * Hologic, Inc. (NASDAQ: HOLX) * I-Mab ADR (NASDAQ: IMAB) * Inari Medical Inc (NASDAQ: NARI) * ITAMAR MED LTD/S ADR (NASDAQ: ITMR) * Meridian Bioscience, Inc. (NASDAQ: VIVO) * Novavax, Inc. (NASDAQ: NVAX) * Pacira Biosciences Inc (NASDAQ: PCRX) ) * Quidel Corporation (NASDAQ: QDEL) * TFF Pharmaceuticals Inc (NASDAQ: TFF) * TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) * West Pharmaceutical Services Inc. (NYSE: WST)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 13) * ADiTx Therapeutics Inc (NASDAQ: ADTX) * Generation Bio Co (NASDAQ: GBIO) * Gritstone Oncology Inc (NASDAQ: GRTS) (reacted to Phase 1 readouts of its cancer vaccine candidates) * INVENTIVA SA/ADR (NASDAQ: IVA) (went public Friday) * NextCure Inc (NASDAQ: NXTC) (said it is pulling the plug on NC318 monotherapy study in non-small cell lung and ovarian cancers, and the departure of its chief medical officer) * ORIC Pharmaceuticals Inc (NASDAQ: ORIC) * Poseida Therapeutics, Inc. (NASDAQ: PSTX) (went public Friday) * Recro Pharma Inc (NASDAQ: REPH) * Repare Therapeutics Inc (NASDAQ: RPTX) * Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN) * VIVUS, Inc. (NASDAQ: VVUS)Stocks In Focus Blueprint Out-Licenses Late-Stage Cancer Drug To Roche For Up To $1.7B Blueprint Medicines Corp (NASDAQ: BPMC) and Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) announced a licensing agreement in which Blueprint will provide exclusive rights to Roche for global co-development and commercialization of pralsetinib outside the U.S., excluding Greater China. Prasetinib is Blueprint's investigational, once-daily oral precision therapy for the treatment of people with RET-altered non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancer, as well as other solid tumours.The companies also said they plan to expand development of pralsetinib in multiple treatment settings and explore development of a next-generation RET inhibitor under the collaboration.The agreement provides for Blueprint receiving an upfront cash payment of $675 million and a $100-million equity investment. In addition, Blueprint is eligible to receive up to $927 million in contingent development, regulatory and sales-based milestones, and royalties on net product sales outside the U.S.In premarket trading Tuesday, Blueprint shares were jumping 9.59% to $84.FDA Allows Expanded Access To Single Patient For Vanda's Gastroparesis Investigational Therapy Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) said the FDA has allowed a single patient in an Individual Patient Expanded Access protocol, enabling access to continued treatment with tradipitant for gastroparesis beyond the 12 weeks of a Phase 3 study in which he originally participated. The company said the treating physician had judged tradipitant was the only treatment that effectively managed the patient's gastroparesis symptoms.The stock was up 11.8% premarket at $12.70.Eisai, Biogen Begin Late-Stage Study Of Drug To Treat Preclinical Alzheimer's The Alzheimer's Clinical Trials Consortium, along with Biogen Inc (NASDAQ: BIIB) and Eisai Co., Ltd (OTC: ESALY) said a new Phase 3 clinical study -- dubbed AHEAD 3-45 -- of BAN2401, an anti-amyloid beta protofibril antibody, has been initiated in the U.S. for individuals with preclinical Alzheimer's disease.Such patients, according to the companies, are clinically normal and have intermediate or elevated levels of amyloid in their brains. BAN2401 is being studied in a pivotal Phase 3 clinical study in symptomatic early Alzheimer's disease.The AHEAD 3-45 will be conducted in the U.S., Japan, Canada, Australia, Singapore and Europe, the companies said.See also: The Week Ahead In Biotech: J&J Kickstarts Pharma Earnings, Repare Therapeutics IPO Edwards Lifesciences, Abbott Settle Patent Heart Valve Repair Lawsuits Edwards Lifesciences Corp (NYSE: EW) said it has reached an agreement with Abbott Laboratories (NYSE: ABT) to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products.Although the companies said the settlement terms are confidential, Edwards Lifesciences said it will record a one-time settlement expense in the quarter ended June 30 and incur royalty expenses through May 2024.Edwards shares were up 1.95% to $68.50 and Abbott was up 0.89% at $93.92 premarket. Immunomedics, Roche Expand Cancer Drug Collaboration Immunomedics, Inc. (NASDAQ: IMMU) announced an extension of its clinical collaboration with Roche to evaluate Trodelvy, the former's anti-Trop-2 antibody-drug-conjugate, in combination with Tecentriq, the latter's PD-L1-blocking checkpoint inhibitor, in patients with metastatic urothelial cancer and metastatic non-small cell lung cancer.Immunomedics shares were up 2.08% at $40.80 at the time of publication.INmune Reports Positive Early Readout For Alzheimer's Drug INmune Bio Inc (NASDAQ: INMB) reported interim data from its Phase 1b clinical study of its lead drug XPro1595 in Alzheimer's disease, with the data demonstrating XPro1595 decreased neuroinflammation in patients with Alzheimer's disease.XPro1595 decreased white matter free water, a biomarker of neuroinflammation measured by MRI, the company said. "Not only do we see a clear reduction in neuroinflammation, but we also know where in the brain this is occurring, which may inform us on the domains of cognition that might be affected," said CJ Barnum, director of neuroscience at INmune.The stock was jumping 65.54% premarket to $14.65. Verrica's Viral Skin Infection Drug Rejected By FDA Verrica Pharmaceuticals Inc (NASDAQ: VRCA) said the FDA issued a Complete Response Letter regarding the NDA for VP-102, its investigational, proprietary drug-device combination for the treatment of molluscum contagiosum.The company said the CRL required additional chemistry, manufacturing and controls and human factors information, but did not raise any safety or efficacy issues.The decision was expected, as the FDA had previously issued a letter noting deficiencies that precluded discussion of labeling and post-marketing requirements/commitments.The stock was slipping 16.36% to $7.36 in premarket trading Tuesday.VolitionRx Reports Positive Clinical Trial Results For Prognostic COVID-19 Test VolitionRX Ltd (NYSE: VNRX) announced results from two proof-of-concept clinical studies using its Nu.Q assays, with the test showing correlation with more severe COVID-19 cases, implying strong prognostic potential.The company said it is now focused on the completion of larger longitudinal studies that would be needed to support a potential COVID-19 product launch.The stock was soaring 72.86% to $6.05 in premarket trading.Galera Completes Patient Enrollment In Phase 1b/2a Pancreatic Cancer Study Galera Therapeutics Inc (NASDAQ: GRTX) said it has completed patient enrollment in its pilot Phase 1b/2a safety and anti-cancer efficacy clinical trial of avasopasem manganese, codenamed GC4419, in combination with stereotactic body radiation therapy, in patients with locally advanced pancreatic cancer.Offerings Osmotica Pharmaceuticals PLC (NASDAQ: OSMT) announced the commencement of a proposed public offering of 5 million ordinary shares. All of the shares are being offered by the company.The stock was falling 17.62% premarket to $6.36.Altimmune said it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering and, to certain investors in lieu thereof, pre-funded warrants to purchase shares of its common stock. All of the securities in the offering will be sold by the company.The stock was trading up 8% at $27 premarket Tuesday.On The Radar Adcom Meetings The FDA's Oncologic Drugs Advisory Committee will discuss GlaxoSmithKline plc's (NYSE: GSK) biologic license application for belantamab mafodotin for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The drug linker technology for the product candidate was licensed from Seattle Genetics, Inc. (NASDAQ: SGEN).Related Link: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates See more from Benzinga * The Week Ahead In Biotech: J&J Kickstarts Pharma Earnings, Relay Therapeutics IPO * The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs * The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease
7/13/2020 8:16:00 PM

XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memoryLA JOLLA, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today reported clinical data demonstrating that its lead drug candidate, XPro1595, decreases neuroinflammation in patients with Alzheimer’s disease. Interim results from a Phase Ib clinical trial show that treatment with XPro1595 decreases white matter free water, a biomarker of neuroinflammation measured by MRI. XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that selectively neutralizes soluble TNF, an inflammatory cytokine implicated in Alzheimer's pathology, without affecting transmembrane TNF or the TNF receptors. Specifically, INmune compared biomarker data obtained from six patients treated with XPro1595 for 12 weeks with data from 25 Alzheimer’s patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) that are part of a natural history database in patients with Alzheimer’s. Over a 12-week period, whole brain inflammation increased by 5.1% in the ADNI patients compared to an increase of 1.7% and a decrease of 2.3% in patients treated weekly with 0.3mg/kg or 1.0mg/kg of XPro1595, respectively. A more detailed analysis revealed a 40.6% reduction in neuroinflammation in the Arcuate Fasciculus in patients treated with XPro1595. The Arcuate Fasciculus is a major white matter anterior/posterior tract (white matter bundle) containing long and short fibers that connects the frontal, parietal and temporal lobes and is important for language and short-term memory. By contrast, the ADNI cohort had a 4.6% increase in Arcuate Fasciculus neuroinflammation.“We are extremely encouraged by these findings at such an early stage in our clinical trial,” said CJ Barnum, Ph.D., Director of Neuroscience at INmune. “Not only do we see a clear reduction in neuroinflammation, but we also know where in the brain this is occurring, which may inform us on the domains of cognition that might be affected.” According to Sharon Cohen, M.D., FRCPC, a neurologist and Medical Director of Toronto Memory Program who is not involved with the clinical trial: “The preliminary results from INmune Bio’s Phase Ib study add to the growing enthusiasm for tackling neuroinflammation in the treatment of Alzheimer’s disease. Furthermore, MRI assessment of free water content in the brain holds promise as an exciting surrogate marker for tracking the impact of such treatment.”  INmune will host a key opinion leader (KOL) event at 8 a.m. EDT tomorrow. A brief presentation of the data by the company will be followed by a panel discussion and Q&A with: * Dr. Rosalyn Lai, a psychiatrist and Principal Investigator at KaRa MINDS in Sydney, Australia, that is enrolling patients in the Phase Ib Alzheimer’s study. * Max Descoteaux, Ph.D., Professor, Computer Science Department, Sherbrooke University, CSO of Imeka and an expert in imaging brain connectivity, from state-of-the-art diffusion MRI acquisition, reconstruction, tractography, processing and visualization. * Judith Jaeger Ph.D., President and Principal Scientist of CognitionMetrics, LLC, an internationally recognized cognitive neuropsychologist.  * Malu Tansey, Ph.D., a professor of Neuroscience and Neurology at the Medical College of the University of Florida, and an internationally recognized expert in neuroinflammation and Alzheimer’s disease. KOL Event InformationTo participate in this event you must register in advance.   After registering, you will receive a confirmation email containing information about joining the webinar. To register and access the live webinar click hereDate: July 14, 2020 Time: 8:00 AM Eastern Time About XPro1595XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF) without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website.  About XPro1595 Clinical TrialXPro1595 is currently being evaluated in Phase Ib clinical trial in Alzheimer’s disease patients who have biomarkers of inflammation to determine if neutralizing soluble TNF can decrease those biomarkers of neuroinflammation. There cannot be any assurance about the results of this trial. Adults (>18 years old) diagnosed with probable Alzheimer’s disease defined by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria, confirmed with inflammatory biomarkers, are being enrolled in this multicenter, Phase Ib open-label study. The study will follow patients during a 12-week period to determine the safety and the ability of XPro1595 to reduce neuroinflammation using a combination of biomarkers of inflammation. The study will examine inflammatory and disease-related biomarkers before treatment, at the halfway point, and at the end. Cognitive and neuropsychiatric symptoms will be also be measured during the trial. The study will identify the dose of XPro1595 to be used in a larger Phase II disease modification study. Clinical sites are located in Australia and include KaRa MINDS in New South Wales, Central Adelaide Local Health Network in South Australia, Austin Health and Alfred Health in Victoria, and The Australian Alzheimer's Research Foundation in Western Australia.         For additional clinical trial details, please refer to https://clinicaltrials.gov/ct2/show/NCT03943264?term=Xpro1595&rank=1About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.  The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer.  INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Forward Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate, Quellor™ and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contact:  David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact:  James Carbonara (646) 755-7412 James@haydenir.com

INmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer’s Disease Prior to Start of AAIC 2020
7/9/2020 1:00:10 PM

LA JOLLA, Calif., July 09, 2020 -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the.

INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS
6/11/2020 1:00:10 PM

INmune Bio, Inc. (INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that the Medicines and Healthcare products Regulatory Agency (MHRA; the UK equivalent of the FDA) has given approval to initiate a Phase I clinical trial of INKmune, a novel therapy to prime the patient’s own NK cells to attack their cancer, in patients with high-risk Myelodysplastic Syndrome (MDS) (EUDRACT 2019-004820-40). This single center Phase I trial will be the first-in-man study using INKmune. Based on the current environment and timetable of its clinical site, INmune Bio is targeting the study initiation in the 2nd half of this year.

Killers at the Crossroad – A Published Review of Innate Immune Cell Potential in Treatment of Cancers Published by Co-Founder and CSO of INmune Bio, Inc.
5/19/2020 1:00:10 PM

INmune Bio, Inc. (INMB) (the “Company”), a clinical-stage immunology company focused on  developing treatments that harness the patient’s innate immune system to fight disease, announced publication of a review article:   Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer in the journal Stem Cells Translational Medicine by May Sabry, PhD and Professor Mark Lowdell, PhD, co-founder and Chief Scientific Officer of INmune Bio, past vice-president (Europe) of the International Society of Cell & Gene Therapy (ISCT) and faculty professor at University College London. The article reviews the potential of harnessing cells of the innate immune system to treat cancer.

INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update
5/14/2020 1:00:10 PM

LA JOLLA, Calif., May 14, 2020 -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system.

INmune Bio Inc’s INB03 Inhibits Cell Migration, Tumor Growth, and Induces Innate Immune Response in Pre-clinical Models of Trastuzumab-Resistant HER2+ Breast Cancer
5/11/2020 1:00:10 PM

INmune Bio, Inc. (INMB) (the “Company”), a clinical-stage immunology company focused on  developing treatments that harness the patient’s innate immune system to fight disease, announced presentation of a study  demonstrating the combination of INB03 with lapatinib reverses resistance to therapy in trastuzumab resistant HER2+ breast cancer. The work lays the groundwork for INmune Bio’s planned Phase II trial and, was chosen for an oral presentation at the New York Academy of Science Frontiers in Cancer Immunotherapy 2020 publication on Monday, 11 May.  Sophi Bruni, a doctoral student in the laboratory of Dr. Roxana Schillaci, in the Lab of Molecular Mechanisms, Instituto de Biología y Medicina Experimental-CONICET, Argentina will be presenting the work.

INmune Bio, Inc. to Host First Quarter 2020 Earnings Conference Call
5/6/2020 8:20:10 PM

INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that it will host a conference call on May 14, 2020 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2020. INmune Bio, Inc. is a publicly traded (INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.

INmune Bio, Inc. to Speak on COVID-19 Therapeutic Panel at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020
4/28/2020 1:00:10 PM

INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that RJ Tesi, MD, CEO and CMO of INmune Bio will participate on a COVID-19 therapeutics panel discussion, at Maxim Group’s Infectious Disease Virtual Conference at 3:45pm ET, on Tuesday, May 5, 2020. Dr. Tesi will discuss treating COVID-19 as an inflammatory disease.

Is INmune Bio (NASDAQ:INMB) In A Good Position To Invest In Growth?
4/28/2020 12:09:37 PM

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Frontiers in Oncology Publishes an Invited Review Highlighting Soluble TNF’s Impact on Breast Cancer
4/23/2020 1:00:10 PM

INmune Bio, Inc. (INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced publication of an invited review in Frontiers in Oncology: Tumor Necrosis Factor α Blockade: an Opportunity to Tackle Breast Cancer, by Dr. Roxana Schillaci, in the Lab of Molecular Mechanisms, Instituto de Biología y Medicina Experimental-CONICET, Argentina.